A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs NYX 2925 (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Aptinyx
- 12 Nov 2019 Status changed from not yet recruiting to recruiting, according to an Aptinyx media release.
- 12 Nov 2019 According to an Aptinyx media release, data from the trial is expected in the first half of 2021.
- 30 Oct 2019 Status changed from planning to not yet recruiting.